TD Cowen lowered the firm’s price target on Biogen (BIIB) to $275 from $300 and keeps a Buy rating on the shares. The firm said they reported Q3 revenue in line and EPS beat. 2024 EPS guidance was raised. Leqembi s launch continues to gain momentum but logistics and capacity constraints remain barriers to adoption.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: